Skip to main content
Glama

Mychem

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.5/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly/idempotent annotations, the description discloses internal cascading lookups, graceful degradation of LEI/FIGI enrichment, exact-ticker versus name-search resolution, coverage of non-equity instruments, ISIN-to-LEI mapping, and the drug result format including a citation. This is substantial behavioral context an agent needs.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with purpose and usage guidance, and each clause carries behavioral or semantic value. However, it is a long single paragraph with a promotional tail ('using resolve_entity replaces 2-3 manual lookups') that is not strictly necessary for invocation. Still well above the minimum viable length.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a two-parameter read-only tool with no output schema, the description covers input formats, return identifiers, supported types, and failure behavior (graceful degradation). It does not explicitly describe ambiguous-result handling such as candidate lists or unresolved fields, but this is a minor gap rather than a critical one.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so the baseline is 3. The description adds that company input accepts ISIN, explains exact-ticker vs name-search behavior, and clarifies drug accepts brand or generic names. This goes beyond the schema, though the schema's value description already covers most input guidance, so a 4 is appropriate.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete example queries and states exactly what the tool does: 'resolve a user-spoken NAME to the canonical/official identifiers other tools require as input.' It names the verb (resolve), the resource (entities/names), and the output (canonical identifiers), and distinguishes itself from siblings by framing itself as the prerequisite ID lookup. Supported types and their specific identifiers are enumerated.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives an explicit trigger: 'Use FIRST whenever you have a name but need an ID.' It also notes that the tool replaces 2-3 manual lookups. However, it does not explicitly name alternative tools or state when not to use it, so it stops short of full routing guidance.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Mychem toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.9/5.0
Disambiguation2/5

The set contains several near-duplicate entry points (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded) plus a dense family of polymarket_* and chemical lookup tools whose boundaries are subtle. An agent can easily pick the wrong router variant, edge-scanning tool, or chemical search tool.

Naming Consistency3/5

Snake_case is used throughout, but naming style is mixed: some tools are verb-first (query, resolve_entity, validate_claim), some are noun/domain-first (entity_profile, recent_changes, polymarket_arbitrage), and the ask_pipeworx variants use suffixes instead of a consistent verb pattern. It is readable, but there is no predictable convention beyond snake_case.

Tool Count2/5

34 tools is well past the comfortable range, and the count is especially hard to justify because they span unrelated domains: chemistry lookups, a Pipeworx data gateway, prediction-market analytics, memory, subscriptions, AI-visibility checks, and npm dependency scanning. Many of these have no obvious connection to the 'Mychem' name or to each other.

Completeness4/5

Within each contained workflow the surface is fairly complete: chemistry has search/fetch/metadata, Pipeworx has lookup/research/discovery/validation, subscriptions and memory both have lifecycle coverage, and the Polymarket family covers research, edge detection, persistence, and fill risk. Some minor gaps exist (no general web retrieval or execution/trading action), but agents can work around them.

Resources